Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Techne (TECH) EBT (2016 - 2025)

Bio-Techne has reported EBT over the past 17 years, most recently at $50.8 million for Q4 2025.

  • Quarterly results put EBT at $50.8 million for Q4 2025, up 18.44% from a year ago — trailing twelve months through Dec 2025 was $27.4 million (down 84.35% YoY), and the annual figure for FY2025 was $11.6 million, down 93.34%.
  • EBT for Q4 2025 was $50.8 million at Bio-Techne, up from $48.0 million in the prior quarter.
  • Over the last five years, EBT for TECH hit a ceiling of $103.7 million in Q3 2022 and a floor of -$176.1 million in Q2 2022.
  • Median EBT over the past 5 years was $48.8 million (2023), compared with a mean of $33.5 million.
  • Biggest five-year swings in EBT: surged 150.16% in 2023 and later tumbled 456.34% in 2025.
  • Bio-Techne's EBT stood at $86.2 million in 2021, then decreased by 22.92% to $66.4 million in 2022, then tumbled by 49.74% to $33.4 million in 2023, then increased by 28.42% to $42.9 million in 2024, then grew by 18.44% to $50.8 million in 2025.
  • The last three reported values for EBT were $50.8 million (Q4 2025), $48.0 million (Q3 2025), and -$109.7 million (Q2 2025) per Business Quant data.